liposomal ciprofloxacin hydrochloride

Liposomal ciprofloxacin hydrochloride is an inhaled antibiotic formulation developed by Aradigm Corporation, consisting of the fluoroquinolone ciprofloxacin encapsulated within liposomes. By utilizing liposomal delivery, the drug achieves sustained release in the lungs, allowing for once-daily dosing and enhanced penetration into bacterial biofilms. It primarily targets bacterial DNA gyrase and topoisomerase IV, inhibiting DNA replication and providing bactericidal activity. The formulation is specifically designed to treat chronic lung infections, including non-cystic fibrosis bronchiectasis (NCFB) and infections caused by *Pseudomonas aeruginosa* or non-tuberculous mycobacteria (NTM). Following the FDA's rejection of a related dual-release formulation and the subsequent liquidation of Aradigm Corporation, development of this specific formulation has largely ceased.

Brand names

Lipoquin

Other names

liposomal ciprofloxacininhaled liposomal ciprofloxacin